Compare ULS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULS | BIO |
|---|---|---|
| Founded | 1894 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 8.2B |
| IPO Year | 2024 | N/A |
| Metric | ULS | BIO |
|---|---|---|
| Price | $80.36 | $304.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $81.75 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 2.5M | 146.2K |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 10.58 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $3,003,000,000.00 | $2,557,500,000.00 |
| Revenue This Year | $7.18 | $1.62 |
| Revenue Next Year | $5.56 | $2.26 |
| P/E Ratio | $48.44 | ★ N/A |
| Revenue Growth | ★ 6.68 | N/A |
| 52 Week Low | $48.54 | $211.43 |
| 52 Week High | $91.95 | $373.69 |
| Indicator | ULS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 47.59 |
| Support Level | $78.49 | $300.26 |
| Resistance Level | $81.41 | $305.62 |
| Average True Range (ATR) | 1.69 | 6.99 |
| MACD | 0.31 | 0.13 |
| Stochastic Oscillator | 73.12 | 53.56 |
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.